GLP-1 receptor agonists (GLP-1RAs) are demonstrating meaningful reproductive signal in women with polycystic ovary syndrome (PCOS). Across 47 reviewed studies (2014–2025), liraglutide (1.2–3.0 mg/day) combined with metformin achieved pregnancy rates of 69.2% versus 35.4% with metformin alone in one randomized trial. Exenatide (10 µg twice daily) plus metformin produced ovulation rates up to 86%. Mechanistically, GLP-1 receptors are expressed in ovarian tissue, and these agents appear to lower androgens, reduce follicular inflammation, and restore granulosa-oocyte communication by suppressing the chemokine CXCL10.
The CXCL10 suppression finding is particularly interesting — it offers a plausible cellular pathway beyond weight loss alone, suggesting GLP-1RAs may act directly on ovarian microenvironment quality rather than merely through metabolic improvement. That distinction matters clinically, because PCOS-related infertility is not purely a weight problem.
However, this is a narrative review — not a meta-analysis or original trial — meaning it synthesizes existing literature without pooled statistical rigor or bias correction. The pregnancy rate figures come from individual trials of varying size and design. Crucially, semaglutide and tirzepatide require an 8–10 week pre-conception washout, and animal data raise fetal safety concerns that have yet to be resolved in humans. Tirzepatide's interference with oral contraceptive absorption via delayed gastric emptying adds an underappreciated contraceptive failure risk. Overall, this is a confirmatory synthesis of emerging evidence — clinically actionable for preconception counseling, but not yet practice-changing without larger, purpose-built fertility RCTs.